Business

A US company called Honu Xpress says that it has acquired a license for the Mystabis cannabis MDI which it claims "provides pressurized metered-doses of cannabis oil directly to the lung's capillaries with little to no exhale" and up to 95% bioavailabilty. The company said that it plans to sell the inhaler in US and foreign markets except for Canada and Australia … [Read more...] about US company licenses cannabis pMDI

Swedish inhaled product developer Iconovo has announced a deal with Japanese pharmaceutical company TOA for development of Iconovo's ICOone unit dose dry powder inhaler for the treatment of asthma and COPD. TOA's Nishihongo facility includes a building dedicated to DPI manufacturing and filling that has been in operation since 2007. According to Iconovo, the … [Read more...] about Iconovo extends deal with TOA, will develop DPI for the Japanese market

Belgian pharmaceutical company UCB has acquired the rights to Proximagen's USL261 midazolam nasal spray for $150 million up front and potential milestone payments of up to $220 million, the company said. An NDA for USL261 is expected to be filed by the end of 2018. Proximagen, a former subsidiary of Upsher-Smith, reported positive Phase 3 results for USL261 in … [Read more...] about UCB acquires midazolam nasal spray from Proximagen

According to Opiant Pharmaceuticals, the National Institutes of Health’s National Institute on Drug Abuse (NIDA) has awarded the company a 3-year grant of about $7.4 million for development of OPNT003 intranasal nalmefene for the treatment of opioid overdose. The company will receive approximately $2.6 million for the first portion of the grant funding period, which … [Read more...] about Opiant gets $7.4 million grant for development of intranasal nalmefene

US health insurer Highmark Inc. has announced that it signed an outcomes-based contract with AstraZeneca for Symbicort that provides for a rebate from AstraZeneca if the inhaler does not reduce COPD or asthma symptoms in line with clinical trial results. Highmark's evaluation of Symbicort performance will be based on "specific pharmacy and medical … [Read more...] about Highmark and AstraZeneca sign outcomes-based agreement regarding Symbicort

Sunovion Pharmaceuticals has launched Lonhala Magnair glycopyrrolate inhalation solution for the treatment of COPD in the US, the company said. Lonhala Magnair, also known as SUN-101/eFlow, was approved by the FDA in December 2017. In May 2017, the FDA issued a complete response letter to Sunovion's initial NDA for Lonhala Magnair, which had been accepted for … [Read more...] about Sunovion launches Lonhala Magnair glycopyrrolate inhalation solution in the US

A Texas-based startup called TFF Pharmaceuticals announced that it raised $14 million in a Series A preferred stock offering and that it plans to use the funds for development of dry powder formulations for the treatment of a wide variety of pulmonary diseases. The company said that it has an exclusive license to thin film freezing (TFF) technology developed at … [Read more...] about TFF Pharmaceuticals raises $14 million for DPI development

According to Arch Biopartners, the US Patent and Trademark Office has issued US Patent 9,925,206, “Compositions and Methods for Treating Bacterial Infection,” which covers the composition of AB569 sodium nitrite/ethylenediaminetetraacetic acid (EDTA), to the University of Cincinnati. Arch acquired an exclusive license for AB569 from the university in March 2016 … [Read more...] about Arch Biopartners gets US patent for its AB569 antibacterial inhalation solution

US-based Convexity Scientific has announced the availability of its Flyp handheld ultrasonic nebulizer, which the company says received FDA clearance in May 2017. The Flyp nebulizer is lighter weight than a smartphone, the company said, with a rechargeable lithium-ion battery, and delivers most medications in about 7 minutes. Convexity is selling the Flyp nebulizer … [Read more...] about Convexity Scientific launches Flyp handheld ultrasonic nebulizer

Evoke Pharma announced that an amendment of its agreement with Mallinckrodt allows for deferral of milestone payments due on acceptance of review of the company's NDA for Gimoti intranasal metoclopramide for the treatment of gastroparesis in women and on final approval. The agreement now allows for a single milestone payment that will be due a year after FDA approval … [Read more...] about Evoke announces modification of agreement with Mallinckrodt on Gimoti development